公开(公告)号：US09775827B2

公开(公告)日：2017-10-03

申请号：US15488002

申请日：2017-04-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D403/10 ,  C07D405/14 ,  C07D403/04 ,  C07D401/10 ,  C07D401/14 ,  A61K31/4035 ,  A61K31/445 ,  A61K31/55 ,  A61K31/325 ,  A61K31/4155 ,  A61K31/4439

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10899752B2

公开(公告)日：2021-01-26

申请号：US16394762

申请日：2019-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D491/107 ,  C07D265/22 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US10548877B2

公开(公告)日：2020-02-04

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Kouji Fuji ,  Tomohiro Ohashi ,  Makoto Fushimi ,  Kei Masuda ,  Tatsuki Koike ,  Takeshi Wakabayashi ,  Jinichi Yonemori ,  Masami Yamada

IPC: A61K31/4192 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61P25/20 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  C07D213/56 ,  C07D231/12 ,  C07D249/06 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

公开(公告)号：US10323027B2

公开(公告)日：2019-06-18

申请号：US15735418

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D265/22 ,  C07D491/107 ,  C07F7/02 ,  A61P25/28 ,  C07D417/10 ,  C07F7/08

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US09789084B2

公开(公告)日：2017-10-17

申请号：US15608565

申请日：2017-05-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/14 ,  A61K31/4035 ,  A61K31/4406 ,  A61K31/045 ,  C07D471/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US10208046B2

公开(公告)日：2019-02-19

申请号：US15311025

申请日：2015-05-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Kenichiro Shimokawa ,  Takuto Kojima ,  Hiroki Sakamoto ,  Ikuo Fujimori ,  Minoru Nakamura ,  Masami Yamada ,  Masataka Murakami ,  Makoto Kamata ,  Shinkichi Suzuki

IPC: A61K31/437 ,  C07D487/04 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH═ or —N═, or a salt thereof.

公开(公告)号：US10087150B2

公开(公告)日：2018-10-02

申请号：US15799379

申请日：2017-10-31

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Takuto Kojima

IPC: C07D265/22 ,  C07D413/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US09878989B2

公开(公告)日：2018-01-30

申请号：US15190642

申请日：2016-06-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masataka Murakami ,  Jinichi Yonemori ,  Takuto Kojima

IPC: C07D471/04 ,  C07D413/14 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D491/107 ,  C07D265/22 ,  C07F7/02 ,  C07D413/04

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07B2200/07 ,  C07D265/22 ,  C07D413/04 ,  C07D413/06 ,  C07D413/10 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D491/107 ,  C07F7/02 ,  C07F7/0814

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

公开(公告)号：US09789083B2

公开(公告)日：2017-10-17

申请号：US15608557

申请日：2017-05-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami Yamada ,  Shinkichi Suzuki ,  Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Makoto Kamata

IPC: C07D209/46 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/14 ,  A61K31/4035 ,  A61K31/445 ,  A61K31/55 ,  A61K31/4439 ,  A61K31/325 ,  A61K31/4155 ,  A61K31/13

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09777005B2

公开(公告)日：2017-10-03

申请号：US14443598

申请日：2013-11-18

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takahiro Sugimoto ,  Minoru Nakamura ,  Hiroki Sakamoto ,  Shinkichi Suzuki ,  Masami Yamada ,  Makoto Kamata ,  Takuto Kojima ,  Ikuo Fujimori ,  Kenichiro Shimokawa

IPC: C07D221/02 ,  A61K31/44 ,  C07D487/04 ,  C07D401/14 ,  C07D405/14 ,  C07D401/06 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D209/46 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D209/46 ,  C07D401/06 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D453/02 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa═ or —N═; X2 is —CRb═ or —N═; X3 is —CRc= or —N═; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.